Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Dec 12, 2024
Data Byte
Candel leads biotech gainers amid wave of data readouts
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Oct 16, 2024
Data Byte
Trio of indications for Bimzelx among FDA’s September label expansions
Agency converts accelerated approvals of Filspari and Retevmo to full
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Jul 3, 2024
Discovery & Translation
Science Spotlight: Epigenetic editor for brain prion silencing, Mopac’s oral biologics and more
BioCentury’s roundup of translational innovations
BioCentury | May 9, 2024
Management Tracks
C-suite changes at Acelyrin could signal reprioritizations in pipeline
With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way
Items per page:
1 - 10 of 237